<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7998">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03002818</url>
  </required_header>
  <id_info>
    <org_study_id>P16-272</org_study_id>
    <nct_id>NCT03002818</nct_id>
  </id_info>
  <brief_title>Quality of Life Measurement in Treatment Naïve Patients With HCV Genotype 1 Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)</brief_title>
  <acronym>HEMATITE</acronym>
  <official_title>Quality of Life Measurement Using Wrist Actigraphy in HCV Genotype 1 Infected, Treatment naïve Patients Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir Tablets and Dasabuvir Tablets (Viekirax®/Exviera®; 3D Regimen): The HEMATITE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, prospective, open-label, single-arm, multicenter, real-life study
      designed to observe the impact of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen
      (Viekirax®/Exviera®, 3D regimen) on total daytime physical activity and fatigue in
      participants with Hepatitis C Virus (HCV) genotype 1 (GT1).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mean daytime physical activity</measure>
    <time_frame>Up to 28 weeks (collect baseline data up to 4 weeks + 12-week treatment + 12-week follow-up)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Fatigue Severity Score (FSS)</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Fatigue assessed by means of Fatigue Severity Scale (FSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Mean Daytime Physical Activity and FSS</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Where fatigue is assessed by means of FSS and physical activity is measured with an electronic activity tracker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <description>SVR12 defined as hepatitis C virus ribonucleic acid (HCV RNA) not detectable 12 weeks after the last actual dose of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen (Viekirax®/Exviera®, 3D regimen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep efficiency</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <description>Sleep efficiency assessed by means of activity tracker</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>HCV Genotype 1 Participants</arm_group_label>
    <description>Participants receiving paritaprevir/ritonavir/ombitasvir with dasabuvir (Viekirax®/Exviera®, 3D regimen)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with CHC, genotype 1, receiving paritaprevir/ritonavir/ombitasvir with
        dasabuvir regimen (3D regimen)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naïve participants

          -  Mono-infected participants with chronic hepatitis C virus (HCV) genotype 1 (GT1)

          -  Non-cirrhotic participants

          -  Participants with debilitating fatigue (Fatigue Severity Scale [FSS] greater than or
             equal to 4)

        Exclusion Criteria:

          -  Participants with sources of fatigue other than HCV (especially, severe depression,
             cancer and hormonal disorders causing clinically significant fatigue)

          -  Participants with conditions that do not allow to adhere to protocol and use of the
             device at investigator's discretion

          -  Participants who are wheelchair dependent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karin Keller</last_name>
    <phone>41 41 399 15 12</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154038</name>
      <address>
        <city>Baar</city>
        <zip>CH-6341</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160197</name>
      <address>
        <city>St.Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 160197, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 160198</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 160198, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>December 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ritonavir</keyword>
  <keyword>Chronic Hepatitis C (HCV)</keyword>
  <keyword>Dasabuvir</keyword>
  <keyword>Paritaprevir</keyword>
  <keyword>Sustained Virological Response</keyword>
  <keyword>Ombitasivir</keyword>
  <keyword>Genotype 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
